Lundbeck’s Board of Directors is responsible for approving the corporate strategy, setting goals for Executive Management, and for ensuring that members of Executive Management and other senior managers have the right qualifications. The Board of Directors also evaluates management performance and management remuneration. Furthermore, the Board of Directors has the overall responsibility for ensuring that adequate internal and external controls are in place, and for identifying and addressing any relevant risks. This responsibility is defined in the Danish Companies Act and stipulated in the rules of procedures for the Board of Directors. The Board of Directors regularly evaluates the business, our financial strategies and policies, and ensures that day-to-day management is carried out in accordance with such policies.
Executive Management reports to the Board of Directors on an ongoing basis regarding:
In 2020, the focus of the Board of Directors was on securing the continued implementation of the corporate strategy that was presented in February 2019. In particular the Board of Directors focused on securing realization of the value associated with the 2019 acquisitions of Abide Therapeutics, Inc. and Alder Biopharmaceuticals, Inc. Both acquisitions contributed to the strategic imperatives of ‘Rebuilding the pipeline’ and ‘Expanding the operating space’. Furthermore and also in relation to the above mentioned strategic imperatives the Board supported the transformation of the approach in R&D having as objective to build the premier neuroscience pipeline with a dynamic and adaptable innovation approach to meet patients’ needs.
Lundbeck’s Board of Directors consists of seven external directors elected by the shareholders at the Annual General Meeting, and three members elected by our Danish employees. Members elected at the Annual General Meeting are up for re-election every year, while the members elected by our employees are up for re-election every four years. In 2020, Lars Rasmussen was re-elected as Chairman and Lene Skole re-elected as Deputy Chairman. There were no changes to the members of the Board in 2020.
Lundbeck promotes and encourages equal opportunities and diversity. Our goals regarding equal opportunities and diversity at Board of Directors level were reached in 2015. According to the goal setting, at least one of the six members elected by the shareholders should be of the underrepresented gender (women). These goals were established in 2013 and should be reached within a four-year period, to allow for continuity of the board. In terms of the 2020 board composition, there is one female board member elected by the shareholders and one elected by Lundbeck’s employees.
Lundbeck has a two-tier board structure consisting of the Board of Directors and Executive Management. No board member is a member of Lundbeck’s Executive Management. Nasdaq Copenhagen recommends that at least half of a company’s board members should be independent. The issue of board member independence is particularly relevant for Lundbeck, which has a single principal shareholder, the Lundbeck Foundation, holding 70% of the shares. Based on the guidance from Nasdaq Copenhagen, four of the six board members elected at the Annual General Meeting are independent, while two members, due to their close affiliation with the Foundation, are not. The Foundation does not nominate the chairman of Lundbeck’s Board of Directors, but only recommends members for the position of deputy chairman and two ordinary board members.
Every year, Lundbeck’s Board of Directors and Executive Management conduct a self-evaluation to assess strengths and weaknesses of the work performed by the Board and the committees. Based on the outcome, changes to the Board of Directors’ working procedures are discussed and any proposals for improvement are considered.
The 2020 evaluation built on the evaluation performed in 2019 with all members of the Board of Directors and Executive Management participating. It was conducted with support from an external provider and concluded a high level of satisfaction with the collaboration and interaction between the Board of Directors and Executive Management, which is described as transparent, constructive, effective and involving. The Board represents a broad set of competencies and knowledge relevant for the company and its future strategic path. However, it is believed that the composition can be improved by adding even more relevant scientific expertise. To meet this objective the Board is currently working towards expanding the scientific knowledge in the Board.
The general procedure for the evaluation of the Board of Directors can be found here.
The procedure for selection and nomination of board candidates can be found here.
The Board of Directors analyses the company’s need for capital on an ongoing basis, including an assessment of the company’s capital structure.
There is no universal answer to the question of what the optimum capital structure is for a specific company because the relationship between equity and interest-bearing debt relies on the specific characteristics that apply within the particular industry in which the business operates and, by extension, the operating and financial risk. However, companies in the pharmaceutical industry are often particularly well-funded which may be explained by the extended development projects and risks associated with research activities.
The Board of Directors pursues the policy that equity beyond the level which, based on a conservative estimate, would be considered sufficient to support the underlying business should be distributed to the shareholders. The distribution to our shareholders takes place through annual dividends and if appropriate share buyback programs.
The Chairman and Deputy Chairman ensure that the Board of Directors’ tasks and responsibilities are handled in a balanced and satisfactory manner. In addition to activities related to strategic, financial and operational supervision of Executive Management. In March 2016, the Board of Directors elected Lars Søren Rasmussen as Chairman and Lene Skole-Sørensen as Deputy Chairman, and they have annually been re-elected at the annual general meetings since then.
The Board of Directors has set up three advisory committees: The Audit Committee, the Remuneration & Nomination Committee and the Scientific Committee. The three committees advise the Board on financial information and reporting, the company’s remuneration and nomination strategy including remuneration of Executive Management, and R&D, respectively. The Chairman of the Board of Directors is not Chairman of the Audit Committee.
The Audit Committee provides advice to the Board of Directors on internal and external controls in financial reporting procedures,
special financial and accounting issues, evaluation of financial reporting and other financial information and risk management issues.
The Audit Committee provides advice on the basis of:
In March 2021, the Board of Directors elected Dorothea Wenzel as Chairman and re-elected Lars Søren Rasmussen and Lars Erik Holmqvist as members of the Audit Committee. The Chairman of the Board does not act as Chairman of the Audit Committee and more than half of the members are independent.
The charter for the Audit Committee can be found here.
The Remuneration & Nomination Committee informs the Board of Directors of remuneration and nomination decisions regarding members of Executive Management. The Committee also advises on the company’s overall remuneration policy and prepares the remuneration report. Additionally, the Committee handles assignments related to recruitment and appointments to Lundbeck’s Board of Directors and to the senior
management. and annually assesses the composition and results of the Board, the Executive Management and the Committees.
In March 2021, the members of the Remuneration & Nomination Committee were re-elected and includes Lars Søren Rasmussen as Chairman and Lene Skole-Sørensen and Jefferey Berkowitz as members. More than half of the members in the Remuneration & Nomination Committee are
The Remuneration & Nomination Committee Terms of Reference can be found here.
Lundbeck’s Board of Directors has a Scientific Committee, the purpose of which is to advise the Board of Directors on support for strategic research and development.
In March 2021, the Board of Directors re-elected Jeremy Max Levin as Chairman and Lene Skole-Sørensen, Jeffrey Berkowitz and Santiago Arroyo as members of the Scientific Committee.
The charter for the Scientific Committee can be found here.
|Member of the Board||Board of Directors||Audit Committee||Remuneration & Nomination Committee||Scientific Committee|
|Lars Søren Rasmussen||7/0||6/0||4/0||1/0*|
|Lars Erik Holmqvist||6/1||6/0||-||1/0*|
|Jeremy Max Levin||7/0||-||-||4/0|
|Rikke Kruse Andreasen||7/0||-||-||-|
|Henrik Sindal Jensen||7/0||-||-||-|
|Ludovic Tranholm Otterbein||7/0||-||-||-|
The numbers indicate how many meetings the members have attended and not attended respectively.
*Complete or partial extraordinary attendance as non-member of the committee.
A decision-making body made up of a two-tier management structure.
Our strategy “Expand and Invest to Grow” aims to deliver sustainable growth.
Board members are responsible for sustainable value creation for all Lundbeck stakeholders.